174 results about "Tissue inflammation" patented technology

The invention relates to an application of a JAK inhibitor in preparation of a medicine for treating chronic kidney diseases, in particular to a compound 2-{N-[4-(4-methyl) piperazine] phenyl} amino-5, 6-dihydro-7-[3-(N-tert-butyl) sulfonamido] phenyl-pyrrolo [2, 3-d] pyrimidine or pharmaceutically acceptable salt thereof, and a preparation method of the compound 2-{N-[4-(4-methyl) piperazine] phenyl} amino-5, 6-dihydro-7-[3-(N-tertiary butyl) sulfonamido] phenyl-pyrrolo [2, 3-d] pyrimidine. The invention also relates to application of a pharmaceutical composition containing the compound in preparation of medicines for treating chronic kidney diseases. The compound has good treatment activity on chronic kidney diseases caused by various reasons, can remarkably reduce the inflammatory factor level of kidney tissue, further reduces kidney injury and fibrosis lesion degree, is high in safety, is expected to become a new medicine for treating the chronic kidney diseases, and has wide clinical application prospects.

The invention relates to the technical field of biological medicines, in particular to rhizoma drynariae extracellular vesicles for treating periodontitis by targeting macrophage ETS2 genes as well as a preparation method and application of the rhizoma drynariae extracellular vesicles. The extracellular vesicles are creatively extracted from the traditional Chinese medicine rhizoma drynariae by combining a differential ultracentrifugation method with a sucrose density gradient centrifugation method, the functions of the extracellular vesicles are studied, and it is found that the extracellular vesicles can effectively slow down alveolar bone resorption in a periodontitis state and reduce periodontal soft tissue inflammation and have a good treatment effect on periodontitis. It is found for the first time that the rhizoma drynariae extracellular vesicles can reduce the inflammatory ability of macrophages in an inflammatory state and can reduce expression of proinflammatory factors TNF-alpha and IL-6. The invention has important scientific research value and clinical significance for further development and application of various traditional Chinese medicine plant extracellular vesicles including rhizoma drynariae extracellular vesicles.

Embodiments treat inflammation of a user by applying a first patch on a dermis of the user adjacent to an afferent nerve, the first patch comprising first electrodes, and applying a second patch on the dermis of the user adjacent to a vagus nerve or a vagus nerve connecting branch, the second patch comprising second electrodes. Embodiments generate a treatment protocol during a time period comprising simultaneously applying a first electrical stimuli to the afferent nerve via the first electrodes of the first patch and applying a second electrical stimuli to the vagus nerve or the vagus nerve connecting branch via the second electrodes of the second patch.

The invention relates to the field of biological medicine, and provides application of KAT8 and related substances thereof in resisting mycobacterial infection. In particular to application of a KAT8 protein, a nucleic acid molecule for coding the protein and a KAT8 accelerant in preparation of products for preventing and / or treating mycobacterium tuberculosis and related non-mycobacterium tuberculosis (NTM) infection diseases. The KAT8 can inhibit intracellular proliferation of mycobacteria and relieve inflammation and damage of tissues, provides a new target spot for treatment of mycobacterium infection, and has a wide application prospect.

The invention discloses combined lactobacillus salivarius CCFM1398 for regulating and controlling bone homeostasis and relieving bone resorption and a metagen of the combined lactobacillus salivarius CCFM1398, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius CCFM1398 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that expression of protein level and gene level of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors TNF-alpha, IL-6 and MPO of the orthodontic bone absorption rat is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention provides a construction method and system of a chronic hepatitis B liver tissue inflammation grading prediction model and application. The construction method of the chronic hepatitis B liver tissue inflammation grading prediction model comprises the following steps: S1, screening out a plurality of patients which are diagnosed as chronic hepatitis B through liver tissue biopsy pathology and have clear liver tissue inflammation grading according to inclusion and exclusion standards, and collecting clinical data and serum samples of the patients; s2, performing serum protein N-carbohydrate chain fingerprint spectrum difference analysis on the serum samples of the patients with different ALT levels by adopting an N-carbohydrate fingerprint spectrum technology; s3, on the basis of conventional biochemical indexes and / or N-sugar markers, constructing liver tissue inflammation grading evaluation models under different ALT levels by adopting a binary logistic regression analysis method; and S4, respectively evaluating and selecting the model with the optimal efficiency as a chronic hepatitis B liver tissue inflammation grading prediction model. The chronic hepatitis B liver tissue inflammation grading method can be used for quickly, accurately and noninvasively grading the chronic hepatitis B liver tissue inflammation.

The invention discloses a combined lactobacillus salivarius CCFM1397 for improving osteoblast activity and relieving bone resorption and periodontal tissue damage and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus salivarius combination CCFM1397 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that: the expression of MC3T3-E1 cell osteoprotegerin (OPG) protein and gene level is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors IL-1beta, IL-6 and TNF-alpha and myeloperoxidase MPO of the orthodontic bone absorption rats is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention discloses a traditional Chinese medicine with homology of medicine and food and capable of treating gout and hyperuricemia, and belongs to the field of medicine. The medicinal and edible traditional Chinese medicine capable of treating gout and hyperuricemia is prepared from the following raw materials in parts by weight: 40 to 60g of rhizoma smilacis glabrae, 3 to 7g of rhizoma curcumae longae, 10 to 20g of herba taraxaci, 5 to 15g of herba plantaginis, 10 to 20g of rhizoma polygoni cuspidati, 10 to 20g of polyporus umbellatus, 3 to 7g of radix et rhizoma rhei and According to the traditional Chinese medicine with homology of medicine and food and capable of treating gout hyperuricemia, all the components cooperate with one another to achieve a synergistic effect, on one hand, metabolism can be promoted, blood circulation can be accelerated, microcirculation disturbance conditions can be improved, the tissue inflammation reaction degree can be relieved, and edema and other symptoms can be eliminated; on the other hand, the immune system can be adjusted, the body resistance is enhanced, complications are prevented, and clinical symptoms such as arthralgia and other adverse reactions can be improved.

The invention discloses magnesium-based hydrogen-rich bone cement as well as a preparation method and application thereof. The magnesium-based hydrogen-rich bone cement is prepared by mixing and curing powder and curing liquid, the powder comprises the following components in parts by mass: 50-80 parts of structural powder, 10-15 parts of a bonding consumable, 5-10 parts of a healing accelerant and 15-40 parts of an auxiliary agent, the structural powder comprises reinforcing powder and compatible powder, the reinforcing powder comprises at least one of calcium silicate and calcium phosphate, and the compatible powder comprises at least one of magnesium silicate and magnesium phosphate; the healing accelerant comprises a biodegradable polymer and a magnesium-based material embedded in the biodegradable polymer; and after the powder and the curing liquid are mixed and cured, surface activation treatment is applied, and at least part of the bonded consumables are removed. The magnesium-based hydrogen-rich bone cement disclosed by the invention can be applied to preparation of bone defect repair materials, can relieve local tissue inflammatory response, and is high in oxidation resistance, long in oxidation resistance duration, few in organic residues on the ceramic surface of the bone cement and good in biocompatibility.

The invention belongs to the technical field of application of plant exosomes, and discloses a plant-derived hybrid exosome and application of the plant-derived hybrid exosome in pulmonary fibrosis resistance. After screening a proper proportion, the obtained hybrid exosome has an obvious treatment effect on a mouse with pulmonary fibrosis induced by bleomycin, and the treatment effect is specifically shown as follows: (1) the hybrid exosome can obviously relieve lung inflammatory cell infiltration of the model mouse, protect a pulmonary alveolar structure and relieve the degree of pulmonary fibrosis; (2) the hybrid exosome can effectively reduce the expression levels of TNF-alpha, IL-1beta and IL-6, and can effectively slow down the pulmonary fibrosis process; the lung tissue inflammation is inhibited; and (3) the hybridized exosome inhibits the generation of ECM (extracellular matrix) and inhibits epithelial mesenchymal transition, so that the anti-fibrosis effect is achieved. The plant source hybrid exosome prepared by the invention is wide in plant source, simple in exosome preparation process and low in cost, and provides new possibility for treating pulmonary fibrosis.

The invention relates to a tissue inflammation assessment model construction method and device and electronic equipment, and the method comprises the steps: obtaining a training data set which comprises at least one of ultrasonic quantitative parameters, biochemical test parameters, physiological quantitative parameters and morphological detection quantitative parameters of to-be-tested tissues of multiple subjects, the inflammation detection results of the to-be-detected tissues of the subjects are obtained; training the machine learning model according to the training data set to obtain a tissue inflammation evaluation model; input data of the machine learning model at least comprises at least one of ultrasonic quantitative parameters, biochemical test parameters, physiological quantitative parameters and morphological detection quantitative parameters of to-be-detected tissues of subjects in the training data set, and output data is inflammation detection results of the to-be-detected tissues of the corresponding subjects in the training data set; the ultrasonic quantitative parameters are determined on the basis of echo signals corresponding to ultrasonic signals emitted to the to-be-detected tissue and are used for evaluating parameters of the state of the to-be-detected tissue.

The utility model discloses a carbon fiber physiotherapy lamp tube, which relates to the technical field of physiotherapy instruments and comprises a lampshade, a fixing frame is fixedly connected inside the lampshade, a lamp tube is clamped inside the fixing frame, the lamp tube comprises a lamp tube shell clamped inside the fixing frame, a carbon fiber lamp filament is fixedly connected inside the lamp tube shell, and the carbon fiber lamp filament is fixedly connected inside the lamp tube shell. The two ends of the carbon fiber lamp filament are electrically connected with a lamp panel, the portion, located on the right side of the insulation sleeve, of the surface of the lamp panel is sleeved with heat preservation cotton, and one end of the lamp panel is electrically connected with an electric wire. According to the utility model, the infrared lamp tube is arranged on a specific electromagnetic wave physiotherapy device, so that a wave band which is more suitable for a human body can be irradiated, infrared rays are promoted to penetrate through the corium layer of the human body, and the effects of promoting blood circulation, enhancing the absorption capability of muscles to joint tissue inflammation, relieving arthritis symptoms, promoting soft tissue injury healing and the like are achieved; the body can be relieved and relaxed, and meanwhile, the health state of the body can be improved.

The present invention provides a heat-clearing and damp-removing anti-toxic granule and a preparation method thereof, wherein the heat-clearing and damp-removing anti-toxic granule comprises a main component, which comprises, by weight, 280-320 parts of patchouli, 280-320 parts of boiled bitter almonds, 280-320 parts of mulberry leaves, 190-210 parts of cardamom, 280-320 parts of wine scutellaria, 280-320 parts of forsythia, 280-320 parts of tuckahoe, 280-320 parts of talc, 490-510 parts of coix seeds, 190-210 parts of liquorice tablets, and 90-110 parts of cicada shells. The heat-clearing and damp-removing anti-toxic granule provided by the present invention realizes heat-clearing and damp-removing anti-toxic, can inhibit lung tissue inflammation, and alleviate lung damage.

The present application relates to the use of benzamide derivatives in pharmaceutical preparations for preventing and treating inflammatory injuries. The applicant has found that benzamide derivatives can be used as pharmaceutical preparations for preventing and / or treating cellular inflammatory damage caused by factors such as radiation or microbial infection. In some of the embodiments, it is demonstrated that benzamide derivatives have the effects of inhibiting cell pyroptosis, promoting the healing of radiation-complex injuries in mice, and reducing tissue inflammatory responses induced by the new coronavirus pseudovirus.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The utility model discloses a poly (p-dioxanone) medical suture with an anti-inflammation capsule, and relates to the technical field of medical sutures. The protein anti-inflammatory suture line comprises a suture line inner core, a protein adhesive layer, a protein microcapsule and anti-inflammatory drug particles, wherein the suture line inner core is made of a PPDO material. According to the utility model, the anti-inflammatory drug of the wound can be fully and comprehensively absorbed; the inner core of the suture line has good compatibility, and rejection and tissue inflammation are reduced; the suture line can be gradually degraded in the body and finally converted into carbon dioxide, water and the like, and the carbon dioxide, the water and the like are naturally discharged by the human body and do not need to be removed through a secondary operation, so that the infection risk possibly caused by the secondary operation is reduced, and the infection risk is reduced; the suture line has long strength maintenance time and can provide continuous support for the wound until the tissue is healed; the protein microcapsules and the anti-inflammatory drug particles are beneficial to reducing inflammatory reaction.

The invention discloses a histone-derived peptide nano-particle for targeted degradation of cytoplasm cGAS and a preparation method and application thereof, and is characterized in that a polypeptide compound is dissolved in a phosphate buffer, ultrasonic treatment and room temperature standing self-assembly are performed to form nano-particles, and centrifugal purification is performed to obtain the histone-derived peptide nano-particle A4-CMA NPs for targeted degradation of cytoplasm cGAS. The nano-particles (A4 at CMA NPs) can be combined with cytoplasm cGAS in a targeted manner and mediate the cytoplasm cGAS to degrade, so that the activation of a cGAS-STING pathway is blocked, periodontal tissue inflammation and alveolar bone resorption are effectively relieved, and a new strategy is provided for periodontitis treatment.

The application relates to the field of high polymer materials, in particular to an exosome composite material for treating periodontitis and a preparation method thereof. The exosome composite material comprises the following raw materials in parts by weight: 10-20 parts of a chitosan derivative, 10-20 parts of sodium hyaluronate, 1-5 parts of zein, 0.5-1 part of exosomes, 0.1-0.3 parts of phosphonodipeptide sodium and 60-70 parts of deionized water. The exosome composite material can inhibit periodontal pathogenic bacteria, reduce the expression of proinflammatory factors by inhibiting the signal pathways such as NF-kappa B, and thus relieve periodontal tissue inflammation.

The invention discloses a periodontitis marker and application thereof. Belongs to the technical field of biomedical detection. Experiments prove that the expression of the hsacirc0005737 in patient tissues, periodontal ligament stem cells in an inflammation microenvironment and periodontitis model mouse tissues is remarkably up-regulated, and the expression level of the hsacirc0005737 is positively correlated with the severity and activity of periodontitis. Therefore, detection of the expression level can be used for diagnosis, activity evaluation, curative effect monitoring and prognosis of periodontitis. In addition, the osteogenic differentiation capacity and inflammatory response of the periodontal ligament stem cells can be influenced by regulating the expression of the hsacirc0005737, so that the hsacirc0005737 can be used as a potential target for treating periodontitis. The invention further provides a primer sequence, a detection reagent combination and a kit for detecting the hsacirc0005737, and a new solution is provided for noninvasive, early-stage and high-specificity diagnosis and targeted therapy of periodontitis.

The invention relates to an intestinal tissue inflammation injury treatment target spot and application thereof, and belongs to the technical field of biological medicine. It is found that the level of DPF2 in intestinal tissue inflammation damage can significantly affect regeneration and repair of intestinal tissue, high-level DPF2 can promote intestinal tissue inflammation damage, and after the DPF2 gene is knocked out, intestinal tissue inflammation damage can be significantly reduced. Clinical intestinal tissues are subjected to DPF2 immunostaining, clinical cases are divided into a high-inflammation injury group and a low-inflammation injury group, the high-inflammation injury group shows a higher DPF2 level, it is indicated that DPF2 can indeed serve as a new index for evaluating and diagnosing intestinal tissue inflammation injury, and the DPF2 has a good clinical application prospect.

This invention discloses a histone-derived peptide nanoparticle targeting the degradation of cytoplasmic cGAS, its preparation method, and its applications. The invention is characterized by: dissolving a peptide complex in phosphate buffer, sonicating, allowing it to self-assemble at room temperature to form nanoparticles, and purifying by centrifugation to obtain histone-derived peptide nanoparticles A4@CMA NPs targeting the degradation of cytoplasmic cGAS. These nanoparticles (A4@CMA NPs) can target and bind to cytoplasmic cGAS, mediating its degradation, blocking the activation of the cGAS-STING pathway, effectively reducing periodontal inflammation and alveolar bone resorption, and providing a new strategy for the treatment of periodontitis.

The invention discloses a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of honey-fried ephedra, 3-10 parts of scutellaria baicalensis, 9-15 parts of momordica grosvenori, 9-15 parts of rhizoma dioscoreae nipponicae, 5-10 parts of scalded semen armeniacae amarae, 2-10 parts of liquorice, 3-10 parts of fried fructus perillae, 3-9 parts of fried semen brassicae, 5-10 parts of schizonepeta, 3-10 parts of platycodon grandiflorum and 5-12 parts of fried semen raphani. The pharmaceutical composition disclosed by the invention is a pure traditional Chinese medicine preparation, and can be used for reducing the level of eosinophilic granulocytes, increasing the number of alveolar macrophages and effectively improving abnormal immune response in an asthma process; lesion degrees such as lung tissue inflammatory cell infiltration, alveolar wall edema and goblet cell hyperplasia are relieved; secretion of Th2 type inflammatory cell related factors and IgE is reduced, and finally the effect of treating allergic asthma inflammatory response is achieved.

The present invention discloses a coumarin HDAC6 inhibitor and its preparation method and application, belonging to the field of chemical medicine technology. The present invention provides coumarin compounds shown in Formula I, Formula II and Formula III. Based on the structure of coumarin, the characteristic group of HDAC6 inhibitor hydroxamic acid is introduced to achieve good homologous selectivity for HDAC1 / 6; at the enzyme level, cell level and animal experiment level, it is verified that the compound has excellent target inhibition effect; by studying the example of HDAC6-NF-κB participating in the inflammatory response of colonic tissue, a new practical basis is provided for the treatment of ulcerative colitis. The compound provided by the present invention can be used as a new HDAC6 inhibitor to prevent and treat HDAC6-related diseases, especially it is expected to solve the shortcomings of some current small molecule drugs for the treatment of ulcerative colitis, such as poor relief effect and large side effects.

Disclosed are methods, systems, media, apparatus, devices, and other implementations, including a method that includes determining blood flow characteristics at an ocular surface of an eye of a patient, determining characteristics of blood vessels at the ocular surface of the eye based on the determined blood flow characteristics, and deriving one or more ocular redness grading scales indicative of inflammation levels of the eye of the patient based on the determined characteristics of the blood vessels at the ocular surface of the eye.

An agent for an arrest of dental caries is a silver complex fluoride (SCF) of the structure: [Ag(1,3,5-triaza-7-phosphaadamantane)2]F, (Ag(PTA)2F). The agent effectively arrests dental caries and promotes remineralization of carious lesions. The agent results in minimal staining of teeth and tissue inflammation. The therapeutic agent can be applied selectively to a site of caries or other damaged tissue in the oral cavity.

The present application relates to the technical field of medical devices, and particularly relates to a controlled release device, a preparation method thereof and an intelligent microneedle closed loop system. The controlled release device comprises a metal microneedle, a doped polypyrrole film coated on the surface of the metal microneedle and a drug loaded on the doped polypyrrole film. The controlled release device realizes the electrically controlled on-demand release of hypoglycemic drugs, and can make metformin release 41.1 mu g in 400 minutes, thereby providing a new possibility for personalized treatment of diabetes. Meanwhile, the present application also constructs an intelligent microneedle closed loop system by using a microneedle sensor, realizes real-time monitoring of blood glucose and linkage control of on-demand drug delivery, and can be continuously worn for seven days without tissue inflammation.

The present invention discloses an application of an immunomodulatory peptide in the preparation of a drug for preventing and treating bacterial infection, and belongs to the field of biomedical technology; the rice-derived immunomodulatory peptide RDP3 can inhibit bacterial infection in mice, and can alleviate the inflammatory damage of the lung tissue of infected mice and reduce the level of inflammatory factor protein in the serum of infected mice to a certain extent, and can also improve the survival rate of sepsis model mice. RDP3 exerts an antibacterial effect by recruiting phagocytes to the infected site. In view of the unique antibacterial mechanism of RDP3, it can provide a basis for the research and development of RDP3 as a polypeptide anti-infective drug, and provide candidate molecules for the research and development of peptide antibiotics.

The main purpose set by the present inventors is to provide a technology for suppressing inflammation particularly in aged tissue in the oral cavity.　The present inventors have discovered that it is possible to suppress inflammation particularly in aged tissue in the oral cavity by an oral cavity composition that contains β-glycyrrhetinic acid and at least one selected from the group consisting of retinol acetate, retinol, all-trans-retinoic acid, ascorbic acid, cobalamin, calciferol, anthraquinone, L-histidine, methylhesperidin, and chemically possible salts thereof.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

The present invention relates to a technique for preventing and treating oral soft tissue inflammation and, more specifically, to a novel use of a helium plasma treatment liquid effective for preventing and treating oral soft tissue inflammation and to a composition for alleviating, preventing, and treating oral soft tissue inflammation using same.